AstraZeneca has agreed to take a $2-billion equity stake in Summit Therapeutics, a Miami-based bio/pharmaceutical company, and the companies have formed a clinical collaboration to evaluate Summit’s ...

How are small-molecules faring in 2026? To answer that question, DCAT Value Chain Insights examined where the small-molecules drugs among the 11 drugs identified by Clarivate, a business intelligence ...

Sanofi has expanded its antibody collaboration with Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, to add four new drug candidates in an $8-billion deal ($1 billion ...

Novo has entered into a license agreement with Hengrui Pharma, a Shanghai-based bio/pharmaceutical company, for HRS-1596, a Phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric ...

The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

Roche’s Genentech has broken ground on a $750-million, 211,000-square-foot expansion of its manufacturing facility in Hillsboro, Oregon, to add device fill–finish capabilities, including the ...

The latest from CDMOs, CMOs, and suppliers featuring SK pharmteco, Esteve CDMO, Vetter, Sharp Services, Piramal Pharma Solutions, SPI Pharma, Colorcon, Lonza, and Bespak. Chemicals/Chemical API ...

What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand ...

Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five ...

A recent analysis by Gartner projects low uptake of AI for supply-chain planning decisions by 2030, but AI does factor into ...